Connect
MJA
MJA

The case for newborn screening for congenital adrenal hyperplasia in Australia

Garry L Warne, Katrina L Armstrong, Thomas A Faunce, Bridget M Wilcken, Avihu Boneh, Elizabeth Geelhoed and Maria E Craig
Med J Aust 2010; 192 (2): 107.
Published online: 18 January 2010

To the Editor: We write to encourage policy debate over newborn screening for congenital adrenal hyperplasia (CAH). Classical CAH is a severe, life-threatening disease affecting about one in 15 000 liveborn infants in Australia.1 An inexpensive screening test for newborns is available, but this test is not included in the current newborn screening program in Australia.

  • Garry L Warne1,2
  • Katrina L Armstrong3
  • Thomas A Faunce4
  • Bridget M Wilcken5
  • Avihu Boneh6
  • Elizabeth Geelhoed7
  • Maria E Craig5,2

  • 1 Royal Children’s Hospital, Melbourne, VIC.
  • 2 Australasian Paediatric Endocrine Group, Sydney, NSW.
  • 3 CLAN (Caring and Living As Neighbours), Sydney, NSW.
  • 4 Australian National University, Canberra, ACT.
  • 5 Children’s Hospital at Westmead, Sydney, NSW.
  • 6 Murdoch Childrens Research Institute, Melbourne, VIC.
  • 7 University of Western Australia, Perth, WA.

Correspondence: m.craig@unsw.edu.au

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.